Article Text
Abstract
‘I call him a perfect physician who judges it better to abstain from treatment than pursue one which might perturb the course of the malady’ (Maimonedes, 1125–1204). This might well apply to long-term anticoagulation, with the inevitable risk of bleeding, in a patient with deep venous thrombosis who is found to have factor V Leiden. There is no evidence that the risk of recurrence is any higher than in a comparable patient with no evidence of inherited thrombophilia.
INTRODUCTION
Advances in understanding the pathogenesis of thrombosis have led to a massive increase in laboratory investigations to identify causal factors in affected individuals. However, this approach to investigation, when employed indiscriminately, does not improve clinical management, may cause confusion, and is potentially wasteful of scarce resources. In this article I shall review the inherited and environmental factors contributing to thrombosis, and explore the clinical value of laboratory investigation for prothrombotic
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Testing for thrombophilia: an evidence-based approach
- Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis
- Diagnosis and management of heritable thrombophilias
- Preventing recurrent venous thromboembolism
- Pulmonary embolism: update on management and controversies
- Thrombophilia testing: what do we think the tests mean and what should we do with the results?
- Advances in the management of cardioembolic stroke associated with patent foramen ovale
- Thrombophilia in pregnancy
- Factor V Leiden related Budd-Chiari syndrome
- Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study